Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354273 · ClinicalTrials.gov registry record · Phase 3
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
NCT03354273 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 730 participants.
The verdict
NCT03354273, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
Study Summary
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
Interventions
- DRUG PET MPI
- DRUG SPECT MPI
- DRUG Pharmacological stress agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03354273
The ClinicalTrials.gov registry entry for NCT03354273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET MPI is the first listed.
NCT03354273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03354273 about?
NCT03354273 is a clinical study titled "An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)". This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
What is the current status of trial NCT03354273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2018-06-05. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT03354273?
The interventions under investigation include: PET MPI (DRUG), SPECT MPI (DRUG), Pharmacological stress agents (DRUG).
Who is sponsoring clinical trial NCT03354273?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.